Immune-based therapies for hepatocellular carcinoma
File(s)Immune-based therapies for hepatocellular carcinoma.pdf (2.13 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.
Date Issued
2020-03-10
Date Acceptance
2020-02-25
Citation
Oncogene, 2020, 39 (18), pp.3620-3637
ISSN
0950-9232
Publisher
Springer Nature [academic journals on nature.com]
Start Page
3620
End Page
3637
Journal / Book Title
Oncogene
Volume
39
Issue
18
Copyright Statement
© The Author(s) 2020. This article is published with open access. This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
License URL
Sponsor
AstraZeneca UK Limited
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000518886000005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
PO # 83002 17868
Subjects
Science & Technology
Life Sciences & Biomedicine
Biochemistry & Molecular Biology
Oncology
Cell Biology
Genetics & Heredity
REGULATORY T-CELLS
GROWTH-FACTOR-BETA
CHRONIC HEPATITIS-B
SUPPRESSOR-CELLS
DENDRITIC CELLS
TUMOR MICROENVIRONMENT
DOUBLE-BLIND
TGF-BETA
ADOPTIVE IMMUNOTHERAPY
LIVER-CANCER
Publication Status
Published
Date Publish Online
2020-03-10